GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The second indication for GLP-1 RA is as adjunctive therapy in established type 1 diabetes by blunting glucagon secretion, decreasing gastric emptying, and promoting satiety and weight loss.
“The second indication is as an adjunctive therapy in established type 1 diabetes by blunting glucagon secretion, decreasing gastric emptying, and promoting satiety and weight loss (256).”
Cites
Mathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., Bode, B., & for the ADJUNCT ONE Investigators (2016) · Diabetes Care · doi:10.2337/dc16-0691 · Cited by 347 · see citing works
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699 · see citing works
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116 · see citing works
GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathway
Wu, L., Zhou, M., Li, T., Dong, N., Yi, L., Zhang, Q., & Mi, M. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119300 · Cited by 101 · see citing works
How glucagon-like peptide 1 receptor agonists work
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Endocrine Connections · doi:10.1530/ec-21-0130 · Cited by 71 · see citing works
Minimising hypoglycaemia in the real world: the challenge of insulin
Mathieu, C. (2021) · Diabetologia · doi:10.1007/s00125-020-05354-7 · Cited by 16 · see citing works
- Authors
- Nauck, M. A., & Meier, J. J.
- Affiliations
- St. Josef-Hospital (DE)
- Corresponding author
- Nauck, Michael A
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 8
- Issue
- 4
- Pages
- 262-264
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W3009247057
- Cited by
- 24
- References
- 2
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 2 · 2021: 8 · 2020: 2
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis
- Merck Sharp and Dohme
- Eli Lilly and Company
- AstraZeneca
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- GLP-1 receptor agonists, type 1 diabetes, exenatide, insulin therapy, glycemic control, amylin analogues, SGLT2 inhibitors, metformin
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Blood Glucose, Diabetes Mellitus, Type 1, Double-Blind Method, Humans, Hypoglycemic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
